Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 475 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... October 18, 2021 Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... April 7, 2023 “The power of science”: HPV vaccine proven to dramatically reduce cervical... November 3, 2021 Age and Frailty Should Be Considered Independently When Evaluating Potential Risk... June 27, 2022 Load more HOT NEWS Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line... ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... Why the voices of people affected by cancer are critical to...
